PLAU and idiopathic pulmonary fibrosis: Additional cross-sectional and longitudinal studies with a greater number and diversity (sex, disease stage and rate of progression, treatment history) of subjects will be needed to evaluate whether serum uPA may serve as a biomarker of IPF progression and treatment response.